FORXIGA® (dapagliflozin)

FORXIGA® is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

FORXIGA® is the only SGLT2 inhibitor with UK-specific real world evidence from the CPRD database3

Patients in the UK initiated on FORXIGA® with metformin:

  • Experienced an average reduction in HbA1c of more than 1.1 % when treated for 6 months or longer with FORXIGA®3
  • Results from real-world evidence studies may not necessarily relate to the effect of the intervention/treatment alone. Results should be interpreted in the context of randomised controlled trial findings.

What is CPRD?

  • CPRD stands for Clinical Practice Research Datalink29
  • A governmental, not-for-profit research service, jointly funded by the NHS National Institute for Health Research (NIHR) and the Medicines and Healthcare products Regulatory Agency (MHRA)29
A database of 12,000,000 patient records
A database of 12,000,000 patient records

FORXIGA®’s Real World Evidence Study Details

FORXIGA®’s Real World Evidence Study Details
FORXIGA®’s Real World Evidence Study Details

*FORXIGA® is not indicated for weight loss.1
**FORXIGA® is not indicated for the management of high blood pressure.1
Results from real-world evidence studies may not necessarily relate to the effect of the intervention/treatment alone. Results should be interpreted in the context of randomised controlled trial findings.